Overview

Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)

Status:
Recruiting

Trial end date:
2032-12-31

Target enrollment:

Participant gender:

Summary

This protocol is a phase III study designed to compare the efficacy and the safety of Isa-KRd induction, transplant, Isa-KRd post ASCT consolidation and Isa-KRd light consolidation vs KRd induction, transplant, KRd post ASCT consolidation and KRd light consolidation After confirmation of eligibility criteria patients will be randomized to one of the 2 treatment groups in a 1:1 randomization ratio.

Phase:

Phase 3

Details

Lead Sponsor:

European Myeloma Network

Collaborators:

Amgen
EMN Research Italy
Sanofi

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate
Lenalidomide